Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations. * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 3 months. * At least one measurable extracranial lesion, not previously irradiated and not chosen biopsy during the study screening period. * Prior to enrolling in the study, patients must have central confirmation of T790M+ mutation status from a sample taken after documented progression on the EGFR-TKIs therapy according to cohort. Exclusion Criteria: * Spinal cord compression. * Brain metastases with symptomatic and/or requiring steroid for at least 2 weeks prior to start of study treatment. * Known intracranial hemorrhage which is unrelated to tumor. * Central Nervous System (CNS) complications that require urgent neurosurgical intervention (e.g. resection or shunt placement). * Leptomeningeal metastasis prior to study treatment. * Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD. * Any cardiovascular disease as followed. * History of symptomatic congestive heart failure (CHF) or serious cardiac arrhythmia requiring treatment * History of myocardial infarction or unstable angina within 6 months of the first dose of study treatment * Left ventricular ejection fraction (LVEF)…